Cancer Nursing Today Editors
The editors of Cancer Nursing Today are part of an experienced team of medical writers and researchers who report news and provide commentary related to oncology nursing.
Articles by Cancer Nursing Today Editors
The meeting featured poster presentations, plenary sessions, and more.
The patients receiving a dose adjustment had a mean age of 72.2 years and 42.9% were women.
Patients with relapsed or refractory multiple myeloma are at an increased risk for severe infections.
Researchers conducted a pooled analysis of the MagnetisMM studies.
Nurses involved with the MajesTEC-1 study recommended several practices for infection monitoring and management.
The program hosted meetings for Black patients with mBC and patient advocates to develop educational materials.
The phase III TROPiCS-02 study compared sacituzumab govitecan, an antibody-drug conjugate, with single-agent chemotherapy.
To examine PROs and QOL, the researchers asked patients to complete 3 PRO tools.
At treatment discontinuation, 91% of patients in the FTD/TPI cohort remained at an ECOG performance status of 0 or 1.
APPs play a vital role in early recognition of symptoms of rheumatologic autoimmune diseases in patients with CLL.
Authors of the FRESCO-2 clinical trial reported on treatment-emergent AEs of special interest.
In addition, deepened or sustained responses were also seen in patients who went from weekly to biweekly elranatamab.
The Right Track educational program, created by The Multiple Myeloma Research Foundation, includes 3 critical components.
Dexamethasone can be safely stopped at 6 months in patients with multiple myeloma who have started combination therapies.
The median time to switch from weekly to biweekly or monthly dosing was 11.3 months.
As frontline providers, APPs need to "stay educated on the plethora of information surrounding genomic assays."
All patients had estrogen receptor-positive/HER2-negative advanced breast cancer with ECOG performance status of 0 or 1.
The frequency of veno-occlusive disease, hyperacute and acute GVHD, and chronic GVHD were not different between groups.
Researchers evaluated two categories of immunosuppressive therapy to evaluate the best approach.
Researchers studied more than 14,000 people in Florida.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.